Localization of aurora A and aurora B kinases during interphase: role of the N-terminal domain.: Interphase localization of Aurora kinases A and B by Rannou, Yoann et al.
Localization of aurora A and aurora B kinases during
interphase: role of the N-terminal domain.
Yoann Rannou, Marie-Be´renge`re Troadec, Clotilde Petretti, Fabienne Hans,
Ste´phanie Dutertre, Stefan Dimitrov, Claude Prigent
To cite this version:
Yoann Rannou, Marie-Be´renge`re Troadec, Clotilde Petretti, Fabienne Hans, Ste´phanie
Dutertre, et al.. Localization of aurora A and aurora B kinases during interphase: role of
the N-terminal domain.: Interphase localization of Aurora kinases A and B. Cell Cycle, Taylor
& Francis, 2008, 7 (19), pp.3012-20. <inserm-00319921>
HAL Id: inserm-00319921
http://www.hal.inserm.fr/inserm-00319921
Submitted on 19 Mar 2012
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
 1 
 
 
LOCALIZATION OF AURORA A AND AURORA B KINASES DURING 
INTERPHASE: ROLE OF THE N-TERMINAL DOMAIN. 
 
Yoann Rannou1§, Marie-Bérengère Troadec1§, Clotilde Petretti1, Fabienne Hans3, Stéphanie 
Dutertre2, Stefan Dimitrov3 and Claude Prigent1* 
 
1 - CNRS UMR 6061 Institut de Génétique et Développement de Rennes, Université de Rennes 1, 
IFR140, Rennes, France. 
2 - IFR140 Génétique Fonctionnelle Agronomie et Santé, Université de Rennes 1, 35043 Rennes, 
France.  
3 - CRI INSERM U823 Université Joseph Fourier, Institut Albert Bonniot, Site Santé La Tronche, 
BP170, 38042 Grenoble cedex 9, France. 
 
Running title: Interphase localization of Aurora kinases A and B 
 
§  - these authors contributed equally to the work 
 
Address correspondence to : Claude Prigent, IGDR UMR6061 CNRS UR1, 2 avenue du Pr. Léon 
Bernard, CS 34317, 35043 Rennes cedex, FranceTel : (33) (0)2 23 23 46 93, Fax : (33) (0)2 23 
23 44 78, claude.prigent@univ-rennes1.fr 
 2 
AKNOWLEDGMENTS 
 
We wish to thank Tim Hunt for Xenopus Aur-B cDNA and Diane M Ward for proofreading. The 
images were taken on the Fluorescence Microscopy Platform of the University of Rennes (GIS 
EUROPIA, IFR140). Y Rannou and M-B Troadec were fellows of the Ligue Nationale Contre le 
Cancer, Y Rannou was also a fellow of the Association pour La recherché sur le Cancer. C Petretti 
was a fellow of the Region Bretagne. S Dimitrov was supported the Agence Nationale de la Recherche  
(Project R05075CC) and Rhône-Alpes Canceropôle CLARA (EpiProNetwork). C Prigent was 
supported by the Canceropôle Grand Ouest and the CNRS. S Dimitrov and C Prigent were both 
financed by the “Ligue Nationale Contre le Cancer” (équipes Labellisées). 
 
ABBREVIATIONS 
 
The abbreviations used are: APC/C, Anaphase Promoting Complex/Cyclosome; GFP, Green 
Fluorescence Protein; INCENP, INner CENtromer Protein, MCAK, Mitotic centromere-associated 
kinesin; TACC; Transforming Acidic Coiled Coil protein, TPX2 Targetting Protein for Xklp2,  
 
 
 3 
 
ABSTRACT 
 
Aurora kinases possess a conserved catalytic domain (CD) and a N-terminal domain (ND) that 
varies in size and sequence. We have previously reported that the N-terminal domain of 
AuroraA (AurA) participates in the localization of the kinase to the centrosome in interphase. 
AuroraB (AurB) is a chromosome passenger protein and its N-terminal domain is not necessary 
for its localization or function during mitosis. Using various combinations of GFP-AurA and 
AurB protein domains we show that in interphase, AurB N-terminal domain is required for 
nuclear localization in Xenopus XL2 cells. In human cells, however, we found both AurA and 
AurB kinases in the nucleus, AurA being mainly cytoplasmic and AurB mainly nuclear. Both 
proteins are actively excluded from the nucleus by a CRM1 dependent pathway. Interestingly, at 
a functional level, in interphase, every combination of Aurora kinase domains (ND-CD) rescues 
histone H3 Serine10 phosphorylation defect induced by AurB knockdown. This clearly indicates 
the presence of a functional AurA in the nucleus. Additionally, the chimera ND-AurA/CD-AurB 
was much more efficient than the ND-AurB/CD-AurA to rescue multinucleation also induced by 
AurB knockdown. This indicates that the catalytic domain of AurB is required to fulfill specific 
functions during mitosis that cannot be fulfilled by the catalytic domain of AurA, probably for 
localization reasons during mitosis. 
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INTRODUCTION 
 
The Aurora serine/threonine kinases are essential for normal mitosis to proceed. Mammalian cells 
possess three different Aurora kinases named AurA, -B and -C (AurA, AurB, AurC) 1. AurA is a 
centrosome kinase while AurB and C are chromosome passenger proteins 2 3. All three Aurora 
kinases are overexpressed in numerous cancers 4 5 6, but only AurA transforms NIH3T3 or Rat1 
cells when overexpressed, revealing an oncogenic potential 7 8. AurA activity is required for 
centrosome maturation, and mitotic spindle assembly and stabilization by phosphorylating 
proteins such as TACC, TPX2 and Eg5 9 10 11 12. The kinase also phosphorylates CDC25B 
contributing to the G2/M transition 13. AurB activity is required during the metaphase checkpoint 
to resolve synthelic attachments of chromosome kinetochores through phosphorylation of 
MCAK 14 15. The kinase might also be necessary for chromosome condensation by 
phosphorylating histone H3 16 and for cytokinesis by phosphorylating vimentin, MgcRacGAP 
and the kinesin Mklp1 17 18 19 20. AurB forms at least two different mitotic protein complexes, 
one with INCENP and one with INCENP, survivin, and Borealin 21. The function of AurC is still 
unknown, however the protein overexpressed in HeLa cells behaves like a chromosome passenger 
protein 22 and rescues AurB deficiency 23. Aurora kinases possess three domains; a large catalytic 
domain located in the C-terminal half of the protein, a variable N-terminal non-catalytic domain 
and a very short carboxy-terminal domain 24. Aurora catalytic domains show a high degree of 
identity, whereas, the N-terminal non-catalytic domains are different in sequence and length 
(Figure 1A and B). Xl-AurA and Xl-AurB are 407 and 361 amino acids proteins respectively and 
they share 52% identity (Figure 1C). Their catalytic domains (CD) are very conserved in length 
and sequence (69% identity), while their non-catalytic domains (ND) show only 18% identity 
(Figure 1C). The length of these non-catalytic domains is also different: 138 amino acids in 
length for Xl-AurA and 92 amino acids in length for Xl-AurB 25. Interestingly, these two kinases 
localized differently in interphase cells. AurA begins to localize on duplicated centrosomes in late 
S-phase then stays associated with the centrosomes until early G1-phase 26. At this cell cycle 
stage, AurA is targeted by the APC/C (Anaphase Promoting Complex/Cyclosome) and degraded 
by the proteasome in a Cdh1 dependent manner 27 28. The protein is then resynthesized during 
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the following S-phase and delocalizes to duplicated centrosomes. AurB is a chromosome passenger 
protein 29. It appears only in late G2-phase in the nucleus on chromatin condensation foci and the 
protein is also degraded by the proteasome in a Cdh1 dependent manner 30. In early mitosis, AurB 
localization is restrained to the kinetochores on condensed chromosomes. At the metaphase 
anaphase transition AurB moves from kinetochores to the central spindle and decorates the mid-
body in telophase cells 31. AurB localization during mitosis depends only on the presence of a 
short sequence in the C-terminal domain of the protein. The N-terminal domain of the kinase is 
not required for the mitotic localization or for its mitotic function 32. We previously showed that 
the non-catalytic N-terminal domain of Xl-AurA was able to target the GFP (Green Fluorescent 
protein) to the centrosome mimicking interphase AurA localization 25. We further demonstrated 
that this domain participates to the kinase localization to the centrosome using an active 
mechanism that depends on the presence of microtubules 25. The catalytic domain can also 
localize the GFP to the centrosome but with a much lower efficiency and independently of the 
presence of microtubules. This secondary localization mechanism was proposed to be a passive 
one due to the interaction between Xl-AurA and its substrates already localized on the 
centrosome. The N-terminal domain of the Xl-AurA then plays an essential role in increasing the 
efficiency of the localization of the kinase, at the centrosome 25. AurC is the shortest kinase of 
the family (without N-terminal domain), the kinase is also closely related to AurB, at the 
sequence level but also at the functional level, AurC can rescue AurB RNAi 23. AurC is like an 
AurB without any N-terminal domain. In a previous work we have reported that AurC, in contrast 
to AurB, does not enter the nucleus during G2 33. In this report we asked whether the N-term 
domain of AurB participates to the localization of the kinase during interphase. We found that 
the non-catalytic N-terminal domain of Xl-AurB fused to GFP enters the nucleus in G2 whereas 
the catalytic domain does not. We also show that by switching the N-terminal domains we were 
able to localize Xl-AurB-ND fused to Xl-AurA-CD in the nucleus suggesting that the presence of 
the N-terminal domain of AurB correlates with an increase efficiency in the nuclear localization 
of the kinase. Further analysis of Aurora kinases nuclear localization in human cells showed that 
both AurA and AurB can enter the nucleus. AurA is, however, readily exported in the cytoplasm. 
We also found that proteins containing the catalytic domain of AurA rescue the histone H3 
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Ser10 phosphorylation defect due to AurB RNA interference, but they do not rescue the 
cytokinesis defect. 
 
RESULTS 
 
The N-terminal domain of Xl-AurA and both catalytic domains of Xl-AurA and 
Xl-AurB localize the GFP to centrosome in interphase cel ls. In order to check whether the 
N-terminal of Xl-AurB, like for Xl-AurA, plays any role in the localization processes of Aurora B 
protein during interphase we transfected XL2 Xenopus cells with various Aurora protein domains 
tagged with GFP. As a control, GFP protein alone was also expressed. Xl-AurA is a centrosome 
protein and Xl-AurB a nuclear protein, therefore, we particularly analyzed the protein 
localization at these structures.  
We started by analyzing the centrosomes localization using γ-tubulin indirect 
immunofluorescence as control (Figure 2, panels B1 to B9). When the GFP protein alone was 
expressed, the whole cell (nucleus and cytoplasm) was fluorescent (Figure 2, panels A1 and C1) 
and the centrosomes stained with anti-γ-tubulin were not decorated with GFP (Figure 2, panels B1 
and C1). As we previously reported 25, the AurA-GFP (Figure 2, panels A2 to D2) and the ND-
AurA-GFP proteins (Figure 2, panels A3 to D3) localized to the centrosome when expressed in 
XL2 cells. Eighty-nine ± 4% of interphase cells transfected with AurA-GFP and 80 ± 4% 
transfected with ND-AurA-GFP contained GFP decorated centrosomes (Table 1). Likewise, the 
CD-AurA-GFP protein localized to centrosomes in XL2 interphase cells (Figure 2, panels A4 to 
D4), but with a weaker efficiency, 43 ± 2% of transfected interphase cells contained GFP stained 
centrosomes (Table 1). Therefore, as already reported, we confirm that the ND of Xl-AurA 
participates in the centrosome localization of the protein 25. When the AurB-GFP protein (Figure 
2, panels A5 to D5) or the ND-AurB-GFP protein (Figure 2, panels A6 to D6) were expressed in 
XL2 cells, the fusion protein was never observed at the centrosomes in interphase cells. 
Interestingly, the CD-AurB targeted the GFP to centrosomes in interphase cells (Figure 2, panels 
A7 to D7) with efficiency in the same range than CD-AurA. Fifty-six ± 7% of interphase cells 
expressing CD-AurB-GFP and 43 ± 2% for CD-AurA-GFP exhibited GFP-decorated centrosomes 
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(Table 1). In addition, when the ND-AurA/CD-AurB-GFP protein was expressed in XL2 cells, the 
fusion protein localized to centrosomes in 47 ± 7% of transfected interphase cells (Figure 2, 
panels A8 to D8; table1). ND-AurB/CD-AurA targeted the GFP on centrosomes with the same 
efficiency: 46 ± 5% of transfected cells in interphase (Figure 2, panels A9 to D9; Table 1). 
Although ND-AurA is highly efficient to localize the GFP to centrosome, it loses its efficiency 
when fused to CD-AurB whereas it gains in efficiency when fused to CD-AurA. This suggested that 
there is cooperation between ND-AurA and CD AurA that does not occur between ND-AurA and 
CD-AurB, at the contary. This is also in agreement with the fact that both Aurora-A domains (N-
terminal and catalytic-domain) contain sequences involved in centrosome localization of the 
kinase 34. To summarize, in interphase all the chimera proteins containing either Xl-AurA N-
terminal domain or catalytic-domain localized the GFP to the centrosomes while Xl-AurB was 
found in the centrosome only in the absence of its own N-terminal domain.  
 
The N-terminal domain of Xl-AurB targets all the fusion proteins in the 
nucleus. Because the Xl-AurA N-terminal domain plays a role in localizing Xl-AurA in 
interphase we asked whether the Xl-AurB N-terminal domain would also play a role in the 
localization of Xl-AurB in interphase. All the fusion proteins localized in the cytoplasm, 
especially AurA-GFP, ND-AurA-GFP and CD-AurA-GFP (data not shown). When the AurB-GFP 
was expressed, 96 ± 1% of transfected interphase cells displayed a GFP labeling in the nucleus 
(Table1). This localization was consistent with the previous AurB localization described in 
interphase 20. Ninety-seven% ± 2% of interphase cells expressing ND-AurB-GFP exhibited a 
nuclear GFP staining with the same efficiency than AurB-GFP expressing cells (Table1). The CD-
AurB-GFP never localized in the nucleus (Table1). These results strongly suggest that without its 
N-terminal domain, Xl-AurB can no longer localize to the nucleus. This implies that the Xl-AurB 
non-catalytic domain plays a role in the localization of the protein in interphase XL2 cells. 
Interestingly, none of the AurA domain was able to target the GFP to the nucleus. We then asked 
whether the Xl-AurB non-catalytic domain would be sufficient to target the Xl-AurA catalytic 
domain in the nucleus. When the ND-AurB/CD-AurA-GFP was expressed in XL2 cells, the fusion 
protein was readily found in the nucleus of 96 ± 1% of these cells (Table1). In contrast, the ND-
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AurA/CD-AurB-GFP was never found in the nucleus. All these data strongly confirm that the Xl-
AurB N-terminal domain is essential to localize the protein kinase in the nucleus in XL2 cells.  
 
Both human Aurora A and B kinases are found in the nucleus, but the N-
terminal domain of Hs-AurB increases the nuclear localization efficiency. Xenopus 
XL2 cells are known to be resistant to drug and are also difficult to perform RNA interference on, 
therefore, we decided to study AurA and AurB localization in human Hela cells during interphase. 
AurA and AurB are two proteins highly conserved between Xenopus and Human (Figure 1), 
therefore this study gave us the opportunity to analyze the conservation of localization 
mechanisms from Xenopus to Human.  
We analyzed the nuclear localization of human proteins AurA and AurB tagged with GFP. 
In Human cells we decided to discriminate three kinds of localization : (1) mainly nuclear, (2) 
nuclear and cytoplasmic and (3) mainly cytoplasmic (figure 3A). In agreement with our results in 
XL2 cells, we found that in 74.1 ± 6.1%  of the human HeLa cells Hs-AurB-GFP was mainly 
nuclear, whereas in 25.6 ± 6.1% it was both cytoplasm and nuclear, we didn’t see any cell with 
only cytoplasmic AurB-GFP (Figure 3A). Surprisingly in HeLa cells, Hs-AurA-GFP was equally 
distributed between the cytoplasm and the nucleus in 78.7 ± 3.8% of the cells. In 18.3 ± 2.6% of 
the cells AurA-GFP was nuclear and in only 3% ± 1.6% of the cells the kinase was exclusively 
cytoplasmic. 
We then analyzed the localization of ND-AurB, ND-AurA/CD-AurB and ND-AurB/CD-
AurA tagged with HA (Figure 3C). We changed the tag for practical reasons; those constructs 
have been previously used, controlled and tested 32. 
We first checked whether the localization of the ND of human AurB in human cells was 
the same than the localization of the ND of Xenopus AurB in Xenopus cells. We found that in 
almost 100% of the cells expressing HA-ND-AurB the protein was found in the nucleus, those 
cells were distributed as followed 13.7% ± 1.4% showed a localization mainly nuclear, and 84.9% ± 
1.2% showed an homogenous distribution nucleus and cytoplasm and only 1.4% ± 0.4% a 
localization mainly cytoplasmic (Figure 3C). 
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We then analyzed the localization of chimera proteins. The human chimera HA-BA (ND-
AurB/CD-AurA tagged with HA) localized in the nucleus (72.5% ± 3.4%) like AurB-GFP (Figure 
3B). The human chimera HA-AB (ND-AurA/CD-AurB) was also found in the nucleus (28.8% ± 
6.2%) but with a majority of cells (51.4% ± 5.3%) showing a homogeneous staining within the 
cytoplasm and the nucleus and in 19.8% ± 6.3 of them a localization mainly cytoplasmic (Figure 
3C). These results suggest that the N-terminal domain of Hs-AurB increases the nuclear 
localization efficiency. However it is also clear that to do so the N-terminal of AurB must be 
associated to an Aurora catalytic domain. Indeed AurB is as efficient as HA-BA chimera to 
localize in the nucleus, whereas HA-AB is 2.5 less efficient with a large part (around 20%) being 
now mainly cytoplasmic (Figure 3C). 
 
Hs-AurA and Hs-AurB are actively exported from the nucleus . Hs-AurA and Hs-
AurB proteins have been found in the nucleus of human cells. We examined whether Hs-AurA and 
Hs-AurB exited the nucleus in a CRM1 dependent manner. We used Leptomycin B (LMB) to 
inhibit CRM1 dependent nucleus-to-cytoplasm export. The percentage of cells showing a nuclear 
GFP-staining restricted to the nucleus was indeed enhanced in cell exposed to LMB compared to 
control cells. In the presence of LMB almost 100% (96.4% ± 1.7%) of cells showed AurB-GFP 
exclusively in the nucleus whereas in the case of AurA-GFP it was only 50% (48.4% ± 1.6%) 
(Figure 3D). This means that the whole population of AurB proteins goes to the nucleus whereas a 
subpopulation of AurA never does. The chimera protein HA-BA behaved exactly like the full 
length AurB in the presence or absence of LMB, almost all the cells show nuclear localization 
(Figure 3D and E). At the contrary, the chimera protein HA-AB was not as efficient to localize in 
the nucleus; in this chimera the N-terminal domain of AurB as been replaced by the N-terminal 
domain AurA (Figure 3E). These data indicated that, although the N-terminal domain of AurB 
alone does not preferentially localize to the nucleus, when it is associated with an Aurora kinase 
domain it increases the nuclear localization of the protein (Figure 3C), and plays an important 
role to keep the protein in the nucleus (Figure 3E). 
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The ND-AurB is not required to rescue the multinucleated phenotype induced 
by AurB knock-down. We found that proteins containing the N-terminal domain of AurB were 
more efficiently localized in the nucleus. We then asked whether the presence of this domain was 
sufficient to rescue the loss of histone H3 phosphorylation on S10 in interphase cells and the 
appearance of multinucleated cells due to cytokinesis defects after AurB knock-down by RNA 
interference (Figure 4). AurB was eliminated using small hairpin RNA interference produced by 
pSuper-shAurB as described in Scrittori et al. 2004 (Figure 4B) and the rescue was performed by 
co-transfection of a vector encoding mRNA for either AurA-GFP, AurB-GFP, the HA-tagged 
chimera HA-AB and HA-BA. All constructs were resistant to RNA interference. AurB is 
responsible for the mitotic phosphorylation of the serine 10 of histone H3 16 35. During 
interphase 8‰ of the cells were positive for histone H3 on S10 phosphorylation (H3-S10) (Figure 
4 A and C). These cells correspond to late G2 cells containing nuclear AurB. After AurB knock-
down by RNA interference the amount of interphase cells showing H3-S10 phosphorylation falls 
down to 1.6‰. Overexpression of AurA, AurB, HA-AB or HA-BA in AurB silenced cells restore 
H3-S10 phosphorylation during interphase to a level between 3.8 to 4.6‰. These data suggest 
that overexpression of any Aurora kinase is able to phosphorylate H3-S10 in the nucleus during 
interphase in the absence of endogenous AurB. AurB is also required for cytokinesis 36 20 37. As 
expected, the elimination of AurB induces the appearance of 13.2% of multinucleated cells (Figure 4 
D). We found that the expression of AurB and HA-AB rescued cytokinesis to about 5%. On the 
contrary HA-BA was not efficient to rescue polyploidy since 11.6% of the cells remain 
multinucleated. This result suggests that the presence of the catalytic domain of AurB is necessary to 
avoid multinucleated cell formation seen in AurB knockdown cells.  
 
DISCUSSION 
 
Aurora kinases (A, B and C) are critical at multiple stages of mitosis insuring accurate cell 
division. They regulate centrosome maturation, bipolar spindle assembly and stability, 
chromosome condensation and segregation, spindle checkpoint and cytokinesis 2 6 38. AurA 
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regulates events linked to centrosome/microtubule behavior while AurB and AurC regulate 
interplay between chromosomes and microtubules and also cytokinesis. Aurora kinases are key 
mitotic players that fulfill different function and localize differently during mitosis. The main 
difference between Aurora kinases structures lies in the length and sequence of their N-terminal 
domains; AurA possesses the longest domain and AurC the shortest. It was then tempting to 
suggest that this domain could be involved either in the localization and/or function of the kinase 
during mitosis 25, however, neither AurA nor AurB really need its N-terminal domain to insure its 
localization or its function during mitosis 32. In addition, AurC that possesses only a very short N-
terminal domain can rescue AurB deficiency in mitosis 23. Furthermore a chimera protein 
associating the N-terminal domain of AurA fused to the C-terminal domain of AurB is able to 
rescue AurB mitotic function when depleted by RNA interference 23. All these data, strongly 
suggest that the N-terminal domain of AurB is not required for the kinase function during mitosis. 
So why do Aurora kinases possess a different N-terminal domain? What is the function of this N-
terminal domain?  
We wonder whether the N-terminal domain of AurB could be involved in the localization of the 
kinase during interphase. We were indeed intrigued by the difference in localization of the two 
Aurora kinases A and B during interphase. AurA localizes to the centrosome while AurB never 
does, and AurB is seen in the nucleus at the end of G2 whereas AurA is not.  
We have also previously reported that the non-catalytic domain of AurA increases the 
centrosome localization efficiency during interphase 25. Others have found that a sequence within 
the AurA catalytic domain also participated to centrosome localization together with a sequence 
in the N-terminal 34. So does the non-catalytic domain of AurB play a role in the localization of 
the kinase during interphase?  
We first addressed the question in Xl2 Xenopus cells. We repeated the centrosome localization 
analysis of AurA and included AurB domains and chimera proteins designed with AurA and AurB 
N-terminal and catalytic domains. As previously reported, we found that the N-terminal domain 
and the catalytic domain of AurA localized to the centrosome but the presence of ND-AurA 
increases the efficiency of the centrosome localization. In the case of AurB, the CD-AurB also 
possesses information for centrosome localization; its efficiency to localize to centrosome is 
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comparable to CD-AurorA. In a recent study, we also reported that in human cells GFP-AurC 
localized to centrosome at the end of G2 33. AurC is the smallest Aurora kinase, because it carries 
the smallest N-terminal domain. It seems that every Aurora catalytic domain carries localization 
information sufficient to target GFP to centrosomes. Only the full length AurB and the N-
terminal domain of AurB were never found at the centrosome. We then asked whether AurB N-
terminal domain would also play a role in localizing the kinase in the nucleus during G2, while 
AurA localizes to centrosomes AurB localizes to foci in the nucleus. We decided to analyze the 
nuclear localization of the same proteins in XL2 cells. Only the proteins containing the N-
terminal domain of AurB were seen in the nucleus. The data obtained in Xenopus cell lines were 
then pretty clear, the N-terminal domain of AurB was required to localize the kinase in the 
nucleus.  
We then extended the study to human cell and analyzed the nuclear localization of Aurora 
kinases. We found that although the ND of AurB is important for the presence of the kinase in 
the nucleus, it is not required to enter the nucleus. Indeed, AurB, AurA and all chimera constructs 
accumulate in the nucleus in the presence of LMB, an inhibitor of nuclear to cytoplasm transport. 
The AurB full-length protein and the chimera ND-AurB/CD-AurA show exactly the same 
behavior, about 75% of the cells show nuclear localization of the protein, that increased to about 
95% in the presence of LMB indicating that the protein can use CRM1 to out the nucleus. AurA 
also accumulates in the nucleus in the presence of LMB, but to a much lesser extent indicating 
that a population of AurA remains exclusively cytoplasmic. These data also clearly indicate that 
like AurB, AurA can enter the nucleus. Once in the nucleus both kinases are exported back to the 
cytoplasm by the CRM1 dependent pathway. In the absence of LMB, a large majority of AurB 
stays in the nucleus presumably because it binds to chromosomes and participates to chromosome 
passenger complexes 3. In contrast, AurA has no affinity for chromosomes and is readily 
translocated to the cytoplasm where it binds to the centrosomes. Finally, in this work, we found 
that the N-terminal domain of the Aurora kinase contributes to the different behavior of the 
protein in interphase, the AurA-ND increases the centrosome localization efficiency while the 
AurB-ND contributes to its nuclear localization. We found slight differences between Xenopus and 
human cells, in Xenopus we did not find any construction that enter the nucleus without Xl-ND-
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AurB, while in Human we found that Hs-ND-AurB only increases nuclear localization efficiency.  
At a functional level, AurA, B and all chimeras can rescue H3 S10 phosphorylation defect induced 
by AurB RNAi. However proteins containing the CD of AurA did not rescue multinucleation. 
Even if NT domains help proper localization of Aurora kinases, specific functions are associated 
with their catalytic domains, functions that cannot be fulfilled by a different overexpressed 
Aurora kinase. This is probably a consequence of a localization problem revealed in Scrittori et al, 
2005 32, the CD of AurB possesses a small sequence that is not present in the CD of AurA that is 
required for correct localization during mitotis. This fact has consequences for design of drugs to be 
used in cancer treatment, Aurora kinases being privileged targets 39. 
 
MATERIALS AND METHODS 
 
Cell culture and transfections- Xenopus XL2 cells line 40 were cultured in Leibovitz medium (L15; 
Life Technologies, Inc.) containing 5% fetal calf serum (FCS). Cells were incubated at 25°C. For 
transfection of the various constructs, 5.105 Xenopus XL2 cells were plated out on glass coverslips in 
12-well plate. Cells were transfected with FuGENE 6 transfection reagent (Roche) following the 
manufacturer’s instructions. 
Human HeLa cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) 
supplemented with 10% foetal calf serum (FCS) and penicillin-streptomycin (Invitrogen). For 
transfection experiments HeLa cells were seeded at 2.105 on glass coverslips in 12-well plate. Twenty 
four hours later cells were transfected with 2µg of DNA construct with Lipofectamine2000 reagent 
(Invitrogen) following the manufacturer's instructions. 
Both XL2 and HeLa transfected cells were observed 48h after transfection. 
 
DNA constructs- The sequence of the full-length AurB was amplified by PCR using phy22-GST-AurB 
vector as a template reference (gift from Tim Hunt) and the following primers containing the 
restriction sites 5’- TTT TAC CGC TAG CAT ATG GAG TAC-3’ (NheI) and 5’-GGA CAG CTA 
GCA TGT TTT GAT TGG 3’ (NheI). The sequences of the AurB N-terminal domain (ND) and 
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AurB catalytic domain (CD) were also amplified by PCR using vector Phy22-GST-AurB as a template 
and the following primers containing the restriction sites 5’-TTT TAC CGC TAG CAT ATG GAG 
TAC-3’ (NheI), 5’-CAA TGG GTA CCG TCA TCG ATG GT-3’ (KpnI) and 5’-TTC ACC GGA TCC 
AAT GGA CTT TGA C-3’ (BamHI), 5’GGACAGCTAGCATGTTTTGATTGG3’ (NheI) 
respectively. The resulting PCR fragments were cloned into pGEM-T Easy vector (Promega). The 
PCR fragments encoding full-length (NheI/NheI fragment) and CD-domain (NheI/BamHI fragment) of 
AurB were then subcloned in a modified MCS of pEGFP-N3 (Clontech). The PCR fragment 
corresponding to the ND-domain of AurB was subcloned in the MCS of the pEGFP-N3 using EcoRI 
and KpnI restriction sites. All fusion proteins have the GFP fused to the carboxy-terminal. All these 
constructs were checked by sequencing. 
 
Aurora fusion proteins- We used the three Xenopus AurA constructs previously prepared (Giet and 
Prigent 2001) that encoded Xl-AurA N-terminal domain (ND-AurA-GFP), Xl-AurA catalytic domain 
(CD-AurA-GFP) and the full length Xl-AurA (AurA-GFP). The same three AurB constructs were 
prepared that encoded Xl-AurB N-terminal domain (ND-AurB-GFP), Xl-AurB catalytic domain (CD-
AurB-GFP) and a full length Xl-AurB (AurB-GFP). Two chimera constructs were also used: a Xl-
AurA N-terminal domain fused to Xl-AurB catalytic domain ([ND-AurA/CD-AurB] -GFP) and Xl-
AurB Nterminal domain fused to Xl-AurA catalytic domain ([ND-AurB/CD-AurA]-GFP). 
Expression vectors for various human Aurora constructs (HsAurA-GFP, HsAurB-GFP, Hs-HA-ND-
AurB, Hs-HA-ND-AurA/CD-AurB and Hs-HA-ND-AurB/CD-AurA were kindly provided by S. 
Dimitrov. These constructs have been previously described in Scrittori et al., 2005 32. 
 
ShRNA transfection- HeLa cells were seeded at 2.105 on glass coverslips in 12-well plate. Twenty four 
hours later cells were transfected with 2µg of pSuper-AuroraB construct with Lipofectamine2000 
reagent (Invitrogen) following the manufacturer's instructions. Cells were fixed and stained 48h after 
transfection for observation. 
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Inhibition of CRM1 dependant pathways- Twenty four hours after DNA transfection, HeLa cells were 
treated with Leptomycin B (5 ng/mL; Sigma). Cells were fixed and stained 24h after drug treatment. 
At the same time, control cells were treated with methanol (0.7 ‰). 
 
Immunofluorescence- For analysis of XL2 GFP-transfected cells, these were fixed for 10 min at room 
temperature with 75% methanol, 3.7% formaldehyde in 0.5X PBS and permeabilized for 2 min at RT 
with 0.1% Triton X-100 in PBS. Regarding HeLa transfected cells, they were fixed for 10 min at room 
temperature with 1 M PHEM buffer, 3.7% formaldehyde, 0.2% Triton. Immunostaining of 
centrosomes was performed using a monoclonal anti-γ-tubulin antibody (1/500 in PBS, 3% BSA; 
clone GTU-88; Sigma). Immunostaining of microtubules was performed using a monoclonal anti-α-
tubulin antibody (1/1000 in PBS, 3% BSA; clone YL1/2; Chemicon). Immunostaining of HA-tag 
Aurora protein was performed with a monoclonal mouse anti-HA antibody (1/1000 in PBS, 3% BSA; 
Clone 16B12; Covance). 
Samples were observed under a Leica DMIRE2 inverted confocal microscope or Leica DMRXA2 
fluorescent microscope with a 63x (N.A. 1.32) lens and equipped with standard fluorescence filters. 
Images were acquired with a CoolSnapHQ camera (Roper Scientific) using Metamorph software 
(Universal Imaging) and prepared as single sections or maximum intensity projections before being 
processed in Photoshop 7.0 (v. 7.0; Adobe). 
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FIGURE LEGENDS 
 
Fig. 1: Comparison of Aurora A and B primary sequence between Xenopus and Human. (A) The N-
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terminal domain of AurA and AurB of both Xenopus and human are weakly conserved whereas (B) 
their catalytic domains are well conserved. For instance (C), for Xenopus, AurA and AurB shared 18% 
and 69% of homology between N-terminal and C-terminal domains respectively. 
 
Fig. 2: Centrosomal localization of Xl-AurA-GFP and CD-AurB-GFP proteins in interphase Xl2 cells. 
This panel shows (column (A): overlay, (B) gamma-tubulin immunofluorescence, (C) GFP and (D) 
DNA staining with DAPI within Xl2 cells transfected with the indicated vectors. Original 
magnification x63, scale bar is 10 µm. 
 
Fig. 3: Localisation of GFP-fusion Hs-AurA and Hs-AurB and chimera AurA/AurB in interphase Hela 
cells. (A) Representative images of immunofluorescence used to count cells. Left panel: GFP direct 
observation or HA indirect immunostaining, Right panel: overlay of nucleus staining (DAPI in blue), 
GFP or HA in green and alpha-tubulin in red. Bar is 10 µm, original magnification x63. (B) 
Percentage of GFP positive cells showing GFP-AurA and GFP-AurB staining localized as indicated 
(C) Percentage of HA positive cells showing HA-ND-AurB, HA-AB and HA-BA staining localized as 
indicated (D) Percentage of cells treated with Leptomycin for 24 h and showing GFP-AurA and GFP-
AurB staining localized as indicated (E) Percentage of cells treated with Leptomycin for 24 h and 
showing HA-ND-AurB, HA-AB and HA-BA staining localized as indicated. (B)(C) Statistical tests 
(Mann-Whitney) were performed, for each vector, by comparison between each localization classes, 
*p<0.05. (D)(E) Mann-Whitney test was calculated compared to the situation without Leptomycin B 
*p<0.05, ns non statistically significant. Black is for mainly nuclear, grey for nuclear and cytoplasmic, 
and white for mainly cytoplasmic. HA-AB: HAtag-ND-AurA/CD-AurB; HA-BA: HAtag-ND-
AurB/CD-AurA. 
 
Fig. 4: Functional rescue of Hs-AurB knock-down in Hela cells. (A) Representative images of H3-
phosphoS10 immunofluorescence in interphase cells. Left panel: H3-phosphoS10 staining, right panel: 
merge with nucleus staining (DAPI) Original magnification x40. (B) Western Blot detecting AurB and 
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β-tubulin in HeLa cells after AurB depletion by shRNA. (C) Count of H3-phosphoS10 positive cells in 
interphase. (D) Count of multinucleated cells. Mann-Whitney test was calculated compared to pSuper-
shAurB transfected cells or as indicated by bracket. *p<0.05, HA-AB: HAtag-ND-AurA/CD-AurB; 
HA-BA: HAtag-ND-AurB/CD-AurA. 
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TABLES 
 
Table 1          Localisation of GFP-fusion proteins in Xl2 interphase cells 
 Localization 
Fusion protein centrosomes nucleus 
AurA-GFP 89 ± 4% 0% 
ND-AurA-GFP 80 ± 4% * 0% 
CD-AurA-GFP 43 ± 2% * 0% 
AurB-GFP 0% 96 ± 1% 
ND-AurB-GFP 0% 97 ± 2% ns 
CD-AurB-GFP 56 ± 7% # 0% 
ND-AurA/CD-AurB-GFP 47 ± 7% *# 0% 
ND-AurB/CD-AurA-GFP 46 ± 5% *# 96 ± 1% ns 
 
 
Table 1: Localisation of GFP-fusion proteins in Xl2 interphase cells. 
*p<0.05 compared to full length AurA-GFP protein, #p<0.05 compared to full length AurB-GFP 
protein, ns non statistically significant compared to full length AurB-GFP protein, Mann-Whitney test, 
n=3. 
 




